Poolbeg Pharma PLC (LON:POLB)
5.85p+4.46%
Spriggl Score: Weak— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“US and UK regulators aligned on development path; Summer 2026 cancer trial data is make-or-break.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-indu…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £41.6M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Poolbeg Pharma PLC and 1,600+ UK and US stocks.
Start free